Announced Thu, 16 Jul · 16:32 IST
Board meeting on July 30, 2026 to approve Q1 FY27 results
Results View source PDF
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.0%1-day move
₹2550.00
prior close
₹2546.10
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.4-0.8-0.8-0.7+1.0+1.0-0.4+0.4-1.6—————
Up moveDown movePending
AI summary
Mankind Pharma has informed exchanges that its Board of Directors will meet on July 30, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, i.e. Q1 FY27. The insider trading window remains closed till August 1, 2026. No financial numbers or guidance are disclosed in this intimation, which is purely procedural under SEBI listing rules.
Likely market impact
Routine procedural filing. Investors should watch for the Q1 FY27 earnings announcement after the board meeting on July 30, 2026.